Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Yidu Tech Inc. (2158.HK)
Beijing, CN
Yidu Tech Inc. is a technology company that develops and deploys healthcare solutions leveraging big data and artificial intelligence. Its operations extend across Mainland China, Brunei, and other global regions. The company's business activities are categorized into four core segments: Big Data Platform and Solutions, Life Sciences Solutions, Health Management Platform and Solutions, and a segment for Other ventures. The Big Data Platform and Solutions division provides sophisticated data intelligence platforms and analytics-driven solutions. These offerings cater to hospitals, diverse healthcare institutions, regulatory bodies, and policymakers, aiming to enhance research, clinical diagnosis and treatment, and operational efficiency. This segment specifically includes the provision of DPAP/Eywa platforms for medical organizations. Through its Life Sciences Solutions segment, the company delivers analytical services that support clinical development, real-world evidence (RWE) research, and digital commercialization strategies for pharmaceutical companies, biotechnology firms, and medical device manufacturers. The Health Management Platform and Solutions segment offers health management applications and services, as well as insurance technology (InsurTech) solutions for insurance companies, agencies, and relevant regulators. This segment also includes the distribution of insurance products and the sale of pharmaceuticals and associated hardware. The Others segment encompasses the sale of computer hardware, medical devices, insurance brokerage services, and engagement in medical and computer technology development. Yidu Tech Inc. was established in 2014 and is headquartered in Beijing, China.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.19% | -5.76% | -14.38% | -12.23% | +1.75% | -0.19% | -9.03% | +5.22% | -87.37% | -91.96% | -91.96% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 2 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Healthcare Information Services: +14.2%+10.6% Q1'26: 0.0% (vs Q1'24)
-
EPS growth Medical - Healthcare Information Services: +43.1%+158.9% ★ Q1'26: +171.8% (vs Q1'24)
-
FCF margin FCF growth · Medical - Healthcare Information Services: +49.2%-7.8% Q1'26: +4.3% (vs Q1'24)
-
EBIT margin Medical - Healthcare Information Services: +8.8%-11.4% Q1'26: +6.2% (vs Q1'24)
-
ROIC Medical - Healthcare Information Services: +5.2%-5.5% Q1'26: +6.8% (vs Q1'24)
-
Share dilution Medical - Healthcare Information Services: -0.1%+2.5% Q1'26: +2.4% (vs Q1'24)
-
Debt / EBITDA Net debt/EBITDA · Medical - Healthcare Information Services: -0.74×-1.40× Q1'26: 0.42× (vs Q1'24)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Mar 2021 actual |
Mar 2022 actual |
Mar 2023 actual |
Mar 2024 actual |
Mar 2025 actual |
Mar 2026 2 Rev. Ana. 1 EPS Ana. |
Mar 2027 2 Rev. Ana. 2 EPS Ana. |
Mar 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|
| Revenue |
867.04M
est: 840.22M (+3.2%)
|
1.24B
est: 1.24B (-0.5%)
|
804.70M
est: 865.57M (-7.0%)
|
807.08M
est: 880.19M (-8.3%)
|
714.98M
est: 800.82M (-10.7%)
|
818.71M
814.04M – 823.38M
+2.2% YoY
|
1.05B
962.96M – 1.13B
+27.8% YoY
|
1.32B
1.21B – 1.42B
+25.9% YoY
|
| EBITDA |
-3.65B
est: -442.99M (-724.8%)
|
-715.70M
est: -655.55M (-9.2%)
|
-579.98M
est: -456.35M (-27.1%)
|
-170.77M
est: -464.06M (+63.2%)
|
-89.62M
est: -422.22M (+78.8%)
|
-431.65M
-434.11M – -429.19M
-2.2% YoY
|
-551.69M
-595.69M – -507.70M
-27.8% YoY
|
-694.78M
-750.18M – -639.37M
-25.9% YoY
|
| EBIT |
-3.69B
est: -479.03M (-670.3%)
|
-762.63M
est: -708.88M (-7.6%)
|
-626.33M
est: -493.48M (-26.9%)
|
-217.88M
est: -501.81M (+56.6%)
|
-132.91M
est: -456.57M (+70.9%)
|
-466.77M
-469.43M – -464.10M
-2.2% YoY
|
-596.58M
-644.15M – -549.00M
-27.8% YoY
|
-751.30M
-811.22M – -691.39M
-25.9% YoY
|
| Net Income |
-3.70B
est: -1.08B (-243.2%)
|
-762.32M
est: -814.45M (+6.4%)
|
-627.97M
est: -627.97M (+0.0%)
|
-194.94M
est: -107.81M (-80.8%)
|
-117.79M
est: -126.90M (+7.2%)
|
1.95M
1.75M – 2.15M
+101.5% YoY
|
54.97M
54.20M – 55.74M
+2,718.3% YoY
|
117.76M
105.55M – 129.97M
+114.2% YoY
|
| SGA |
548.95M
est: 459.84M (+19.4%)
|
750.97M
est: 680.49M (+10.4%)
|
503.63M
est: 473.72M (+6.3%)
|
380.21M
est: 481.72M (-21.1%)
|
285.55M
est: 438.28M (-34.8%)
|
448.07M
445.52M – 450.63M
+2.2% YoY
|
572.69M
527.02M – 618.35M
+27.8% YoY
|
721.21M
663.70M – 778.73M
+25.9% YoY
|
| EPS |
-3.99
est: -1.02 (-290.9%)
|
-0.80
est: -0.77 (-3.8%)
|
-0.63
est: -0.62 (-1.6%)
|
-0.19
est: -0.10 (-81.5%)
|
-0.11
est: -0.12 (+8.4%)
|
0.00
0.00 – 0.00
+101.5% YoY
|
0.05
0.05 – 0.05
+2,718.3% YoY
|
0.11
0.10 – 0.12
+114.2% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-28 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-27 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-26 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-22 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-21 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-20 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-19 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-18 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-15 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-14 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-13 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-12 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-11 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-08 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-07 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-06 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-05 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-04 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-30 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-29 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-28 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-27 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-24 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-23 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-22 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-21 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-20 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-17 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-16 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | iShares MSCI China Small-Cap ETF ECNS | 0.27% | 178.4K | 0.59% |
| 2 | Avantis Emerging Markets Small Cap Equity ETF AVEE | 0.05% | 60.2K | 0.42% |
| 3 | iShares MSCI AC Far East ex-Japan Small Cap UCITS ETF ISFE.L | 0.04% | 30.3K | 0.74% |
| 4 | State Street SPDR S&P Emerging Markets Small Cap ETF EWX | 0.03% | 218.4K | 0.65% |
| 5 | iShares MSCI EM Small Cap UCITS ETF IEMS.L | 0.03% | 99.4K | 0.74% |
| 6 | Avantis Emerging Markets Value ETF AVES | 0.03% | 403.2K | 0.36% |
| 7 | iShares MSCI Emerging Markets Small-Cap ETF EEMS | 0.03% | 100.8K | 0.72% |
| 8 | State Street SPDR MSCI Emerging Markets Small Cap UCITS ETF EMSD.L | 0.02% | 112.0K | 0.55% |
| 9 | Avantis Emerging Markets Equity UCITS ETF USD Acc AVEM.L | 0.02% | 44.5K | 0.35% |
| 10 | State Street SPDR Portfolio MSCI Global Stock Market ETF SPGM | 0.01% | 201.1K | 0.09% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Jiming Xu | Co-Founder, Chief Executive Officer & Executive Director | 3M | male |
| Yingying Gong | Founder & Chairlady of the Board | 3M | female |
| Jun Yan | Chief Scientific Advisor | 2M | — |
| Xiaoying Feng | Chief Financial Officer, Joint Company Secretary & Executive Director | 2M | female |
| Ching Yi Li | Joint Company Secretary | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 2158.HK
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
